Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 8/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19663181 | 0.85 | CREBBP (0.45) | PIM1CREBBPMAPTMAP4K1CYP11B1 | |
| SCHEMBL19663194 | 0.85 | PIM1 (0.46) | PIM1CREBBPMAPTMAP4K1CYP11B1 | |
| SCHEMBL19663003 | 0.84 | PIM1 (0.43) | PIM1CREBBPMAPTMAP4K1CYP11B1 | |
| SCHEMBL21237271 | 0.83 | PIM1 (0.47) | PIM1CREBBPMAPTMAP4K1CYP11B1 | |
| SCHEMBL21237239 | 0.82 | FGFR3 (0.46) | PIM1CREBBPMAPTMAP4K1PIM3 | |
| SCHEMBL24367838 | 0.80 | CREBBP (0.42) | PIM1CREBBPMAPTMAP4K1CYP11B1 | |
| SCHEMBL21237190 | 0.80 | CREBBP (0.55) | PIM1CREBBPMAPTPIM3PIM2 | |
| SCHEMBL23762167 | 0.76 | CYP11B1 (0.47) | PIM1CREBBPMAPTCYP11B1CYP11B2 | |
| SCHEMBL25873292 | 0.75 | PIM1 (0.49) | PIM1MAPTCYP11B1CYP11B2PIM3 | |
| SCHEMBL19660420 | 0.74 | PIM1 (0.46) | PIM1CREBBPMAPTMAP4K1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | PIM1 2774/4885CREBBP 3/4885MAPT 2960/4885 |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | PIM1 2774/4885CREBBP 3/4885MAPT 2960/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | PIM1 2774/4885CREBBP 3/4885MAPT 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.